Related Experiment Video

Updated: Aug 11, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Mini-dose glucagon rescue for mild hypoglycaemia in children with type 1 diabetes: the Brisbane experience

Mary Hartley1, Michael J Thomsett, Andrew M Cotterill

  • 1Department of Endocrinology and Diabetes, Mater Children's Hospital, Brisbane, Queensland, Australia.

Journal of Paediatrics and Child Health
|March 3, 2006
PubMed

Insights

Mini-dose glucagon injections effectively manage mild hypoglycemia in children with type 1 diabetes. This practical home treatment reduces hospital visits for young patients experiencing low blood sugar.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Management

Background:

  • Type 1 diabetes management in children requires effective strategies for hypoglycemia.
  • Mild or impending hypoglycemia can be challenging to manage at home, especially when oral carbohydrate intake is difficult.

Purpose of the Study:

  • To evaluate the efficacy and practicality of using small doses of glucagon via insulin syringes for home treatment of mild or impending hypoglycemia in children with type 1 diabetes.

Main Methods:

  • A protocol for home management of hypoglycemia was implemented at a pediatric diabetes clinic.
  • Subcutaneous glucagon injections were administered using insulin syringes with age-adjusted dosing.
  • Additional doses were given if blood glucose did not increase within 20 minutes.

Main Results:

  • 38 instances of mini-dose glucagon treatment were recorded in 25 children over two years.
  • Home management was successful in 84% of cases, with only 16% requiring hospitalization.
  • Recurring hypoglycemia necessitated additional doses in 53% of treatment occasions.

Conclusions:

  • Small-dose glucagon administered subcutaneously with an insulin syringe is a simple and effective home treatment for mild hypoglycemia in children with type 1 diabetes.
  • This method is particularly useful for managing hypoglycemia associated with gastroenteritis or food refusal.
  • The approach offers a practical solution for parents, reducing the need for emergency hospital visits.
Abstract

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...